Akari Therapeutics Q2 EPS $0.00
Portfolio Pulse from Benzinga Newsdesk
Akari Therapeutics reported a Q2 EPS of $0.00, indicating no earnings per share for the quarter.
August 19, 2024 | 8:22 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Akari Therapeutics reported a Q2 EPS of $0.00, which suggests the company did not generate earnings per share for the quarter. This could be a concern for investors looking for profitability.
The EPS of $0.00 suggests that Akari Therapeutics did not generate earnings per share, which could be seen negatively by investors seeking profitability. This may lead to a short-term negative impact on the stock price.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 100